Analysts Give Out "Buy" Ratings to Tech Giants

Today's bull note adds to a big week for AAPL

by Josh Selway

Published on Mar 14, 2019 at 9:55 AM

Analysts this morning have issued new notes on tech stocks Apple Inc. (NASDAQ:AAPL), Microsoft Corporation (NASDAQ:MSFT), and, inc. (NYSE:CRM). Let's take a look at how Wall Street is viewing shares of AAPL, MSFT, and CRM.

It's been a big week for Apple shares, which just notched their highest close since early December. The stock is up another 1.3% today at $184.07, following a fresh "outperform" rating out of Cowen, along with a $220 price target. The bullish note mentioned growth in Apple's services business, upcoming product launches, and stock buybacks as potential tailwinds for the Dow component.

Traders should also monitor short interest on Apple, after the number of shares sold short increased by a shocking 143% in the last reporting period. Nearly 97 million shares are now sold short, or 4.4 times the average daily trading volume. 

Meanwhile, brokerage firm Mizuho said it has a positive view on the software sector as a whole, adding that just 15-20% of work done around the globe is on the cloud, and its top picks are Microsoft and For MSFT, Mizuho started coverage with a "buy" rating and $135 price target, offering nearly 18% upside from current levels. The stock was last seen slightly higher on the day at $114.60.

For Salesforce, it also received a "buy" rating and a price target of $185, well above its all-time high of $166.15 from March 1. The shares were last seen up 0.4% at $160.39, recently bouncing from the 50-day moving average.

a schaeffer's exclusive


Heat up your summer trading with this FREE insider report!



NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories

This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.
3 Drug Stocks Seeing Unusual Options Trading Today
The FDA approved Sesen's request to move manufacturing for its bladder cancer drug
BofA-Merrill Lynch: Buy This Shoe Stock Before Earnings
The brokerage firm thinks the retailer can rally another 26%
This Might Be the Ultimate Cannabis Stock
This innovative company could help investors see some major upside.